VshoRT-R3: Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperatIve treatment in low-moderate risk rectal cancer

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513920-40-00

Enrollment

120

Registered

2024-06-17

Start date

2013-01-11

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low- risk rectal cancel

Brief summary

Fase 1 : MTD capecitabina MTD capecitabina + acido valproico Fase 2: tasso di TRG1

Detailed description

Local control, disease free survival and overall survival. • Pathological CRM negative (margin >1 mm) and lymph node negative rate • Short and long-term toxicity • Surgical Complications • Quality of Life

Interventions

DRUGCAPECITABINE

DRUGVALPROIC ACID

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Fase 1 : MTD capecitabina MTD capecitabina + acido valproico Fase 2: tasso di TRG1	—

Secondary

Measure	Time frame
Local control, disease free survival and overall survival. • Pathological CRM negative (margin >1 mm) and lymph node negative rate • Short and long-term toxicity • Surgical Complications • Quality of Life	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026